FrancophonIA/ELRC3.0 huggingface dataset:
English: Metastatic breast carcinoma, ovarian cancer and non-small cell lung carcinoma: Courses of Paxene should not be repeated until the neutrophil count is at least 1,500 cells/mm3 and the platelet count is at least 100,000 cells/mm3.
Slovenian: Zdravljenja z zdravilom Paxene ne smemo ponoviti, dokler je število nevtrofilcev manjše od 1.500 celic/mm3 in število trombocitov manjše od 100.000 celic/mm3.
English: Rare side-effect are listed below:
Slovenian: Redki neželeni učinki so našteti spodaj:
English: BEFORE YOU USE PAXENE
Slovenian: Ne uporabljajte zdravila Paxene
English: Side-effects may occur while you are receiving Paxene or following treatment.
Slovenian: Med ali po zdravljenju z zdravilom Paxene se bodo pri vas morda pojavili neželeni učinki.
English: Common: tachycardia, palpitation, bradycardia, syncope
Slovenian: Pogosti: tahikardija, palpitacije, bradikardija, omedlevica Občasne: kongestivna srčna odpoved, kardiomiopatija,
English: Very common: minor hypersensitivity reactions (mainly flushing and rash)
Slovenian: Zelo redki*: akutna mieloidna levkemija, mielodisplastični sindrom Bolezni imunskega sistema Zelo pogosti: manjše preobčutljivostne reakcije (večinoma vročinski oblivi in izpuščaji)
English: 150 mg/25 ml
Slovenian: DRUGI PODATKI 100 mg/16,7 ml
English: MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS VIAL TEXT FOR PAXENE 100 mg/16.7 ml
Slovenian: BESEDILO NA VIALI ZA PAXENE 100 mg/16,7 ml
English: MARKETING AUTHORISATION NUMBER(S) EU/1/99/113/002
Slovenian: ŠTEVILKA(E) DOVOLJENJA(DOVOLJENJ) ZA PROMET EU/1/99/113/002
English: • Lack of sleep
Slovenian: • pomanjkanje spanja
English: MARKETING AUTHORISATION NUMBER(S) EU/1/99/113/004
Slovenian: ŠTEVILKA(E) DOVOLJENJA(DOVOLJENJ) ZA PROMET EU/1/99/113/004
English: MARKETING AUTHORISATION NUMBER(S) EU/1/99/113/001
Slovenian: ŠTEVILKA(E) DOVOLJENJA(DOVOLJENJ) ZA PROMET EU/1/99/113/001
English: • Constipation
Slovenian: • zaprtje
English: Very common: anorexia Uncommon: dehydration, weight loss and gain
Slovenian: Občasni: dehidracija, izguba in povečanje telesne mase
English: • Liver damage - yellowing of the skin and abnormal levels of some liver enzymes f you notice any side effects not mentioned in this leaflet, please inform your doctor or pharmacist.
Slovenian: • poškodovanje jeter - porumenelost kože in nenormalne ravni nekaterih jetrnih encimov
English: Common: transient skin change, dry skin, exfoliative dermatitis, pruritis, rash, acne, transient and mild nail
Slovenian: Zelo redki*: nekroza jeter, jetrna encefalopatija Bolezni kože in podkožja Zelo pogosti: alopecija Pogosti: prehodne spremembe na koži, suha koža, eksfoliativni dermatitis, izpiščaj, osip, akne, prehodne in blage spremembe
English: Renal and urinary disorders General disorders and administration site conditions
Slovenian: Splošne težave in spremembe na mestu aplikacije
English: MARKETING AUTHORISATION NUMBER(S) EU/1/99/113/003
Slovenian: ŠTEVILKA(E) DOVOLJENJA(DOVOLJENJ) ZA PROMET EU/1/99/113/003
English: Very common side-effects are listed below:
Slovenian: Zelo pogosti neželeni učinki so našteti spodaj:
English: It is available as an oral solution (100 mg/ml).
Slovenian: Na voljo je kot peroralna raztopina (100 mg/ml).
English: The oral solution may be mixed in a glass of water before it is taken.
Slovenian: Peroralna raztopina se lahko pred zaužitjem zmeša v kozarcu vode.
English: The full EPAR for Levetiracetam Actavis Group can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Levetiracetam Actavis Group je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: This helps levetiracetam to stabilise electrical activity in the brain and prevent seizures.
Slovenian: To omogoča zdravilu levetiracetam, da stabilizira električno aktivnost v možganih in prepreči napade.
English: For more information about treatment with Levetiracetam Actavis Group, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Levetiracetam Actavis Group preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte s svojim zdravnikom ali farmacevtom.
English: This is a summary of the European public assessment report (EPAR) for Levetiracetam Actavis Group.
Slovenian: To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Levetiracetam Actavis Group.
English: This means that Levetiracetam Actavis Group is similar to a ‘reference medicine' already authorised in the European Union (EU) called Keppra.
Slovenian: To pomeni, da je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Keppra.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Levetiracetam Actavis Group on 5 December 2011.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Levetiracetam Actavis Group, veljavno po vsej Evropski uniji, odobrila dne 5. decembra 2011.
English: Because Levetiracetam Actavis Group is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Slovenian: Ker je zdravilo Levetiracetam Actavis Group generično zdravilo in je biološko enakovredno referenčnemu zdravilu, so koristi in tveganja enaki kot pri referenčnem zdravilu.
English: Levetiracetam Actavis Group must not be used in people who are hypersensitive (allergic) to levetiracetam, to other pyrrolidone derivatives (medicines with a similar structure to levetiracetam), or to any of the other ingredients.
Slovenian: Zdravila Levetiracetam Actavis Group ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) levetiracetam ali druge pirolidonske derivate (zdravila s podobno zgradbo kot levetiracetam) ali na katero koli drugo sestavino zdravila.
English: The most common side effects with Levetiracetam Actavis Group (seen in more than 1 patient in 10) are somnolence (sleepiness), and asthenia (weakness) or fatigue (tiredness).
Slovenian: Najpogostejši neželeni učinki zdravila Levetiracetam Actavis Group (opaženi pri več kot 1 bolniku od 10) so zaspanost in astenija (splošna oslabelost) ali utrujenost.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Levetiracetam Actavis Group.
Slovenian: Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Levetiracetam Actavis Group, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
English: When Levetiracetam Actavis Group is added to another anti-epileptic treatment, the starting dose in patients over 12 years weighing more than 50 kg is 500 mg twice a day.
Slovenian: Kadar se zdravilo Levetiracetam Actavis Group dodaja drugemu zdravilu proti epilepsiji, je začetni odmerek pri bolnikih, starejših od 12 let, ki tehtajo več kot 50 kg, 500 mg dvakrat dnevno.
English: The Committee recommended that Levetiracetam Actavis Group be given marketing authorisation.
Slovenian: Odbor je priporočil, da se za zdravilo Levetiracetam Actavis Group odobri dovoljenje za promet.
English: Levetiracetam Actavis Group can also be used as an add-on to other anti-epileptic medicines to treat:
Slovenian: Zdravilo Levetiracetam Actavis Group se lahko uporablja kot dopolnilno zdravljenje k drugim zdravilom proti epilepsiji za zdravljenje:
English: Other information about Levetiracetam Actavis Group
Slovenian: Druge informacije o zdravilu Levetiracetam Actavis Group
English: The CHMP concluded that, in accordance with EU requirements, Levetiracetam Actavis Group has been shown to have comparable quality and to be bioequivalent to Keppra.
Slovenian: Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Levetiracetam Actavis Group primerljivo raven kakovosti kot zdravilo Keppra ter da mu je biološko enakovredno.
English: Because Levetiracetam Actavis Group is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Keppra.
Slovenian: Ker je zdravilo Levetiracetam Actavis Group generično zdravilo, so bile študije omejene na preskuse za ugotavljanje, ali je biološko enakovredno referenčnemu zdravilu Keppra.
English: Levetiracetam Actavis Group is a ‘generic medicine'.
Slovenian: Levetiracetam Actavis Group je „generično zdravilo“.
English: Levetiracetam Actavis Group can be used on its own in patients from 16 years of age with newly diagnosed epilepsy, to treat partial-onset seizures (fits) with or without secondary generalisation.
Slovenian: Zdravilo Levetiracetam Actavis Group se lahko uporablja kot samostojno zdravilo pri bolnikih, starejših od 16 let, pri katerih je bila na novo ugotovljena epilepsija, za zdravljenje napadov parcialnega izvora s sekundarno generalizacijo ali brez nje.
English: What benefit has Levetiracetam Actavis Group shown during the studies?
Slovenian: Kakšne koristi je zdravilo Levetiracetam Actavis Group pokazalo med študijami?
English: Levetiracetam Actavis Group is a medicine that contains the active substance levetiracetam.
Slovenian: Levetiracetam Actavis Group je zdravilo, ki vsebuje zdravilno učinkovino levetiracetam.
English: • myoclonic seizures (short, shock-like jerks of a muscle or group of muscles) in patients from
Slovenian: • miokloničnih napadov (kratkih, krču podobnih sunkovitih gibov mišice ali skupine mišic) pri bolnikih z juvenilno mioklonično epilepsijo od 12. leta starosti dalje;
English: When Levetiracetam Actavis Group is used on its own, the starting dose is 250 mg twice a day, increasing two weeks later to 500 mg twice a day.
Slovenian: Začetni samostojni odmerek zdravila Levetiracetam Actavis Group je 250 mg dvakrat dnevno, po dveh tednih jemanja pa se poveča na 500 mg dvakrat dnevno.
English: The active substance in Levetiracetam Actavis Group, levetiracetam, is an anti-epileptic medicine.
Slovenian: Zdravilna učinkovina zdravila Levetiracetam Actavis Group, levetiracetam, je zdravilo proti epilepsiji.
English: In babies aged between one and six months, the starting dose is 7 mg/kg twice a day, using the oral solution.
Slovenian: Pri otrocih, starih od enega do šestega meseca, začetni odmerek v obliki peroralne raztopine znaša 7 mg/kg dvakrat dnevno.
English: What is the risk associated with Levetiracetam Actavis Group?
Slovenian: Kakšna tveganja so povezana z zdravilom Levetiracetam Actavis Group?
English: Why has Levetiracetam Actavis Group been approved?
Slovenian: Zakaj je bilo zdravilo Levetiracetam Actavis Group odobreno?
English: For the full list of all side effects reported with Levetiracetam Actavis Group, see the package leaflet.
Slovenian: Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi tega cepiva, glejte navodilo za uporabo.
English: What is Levetiracetam Actavis Group?
Slovenian: Kaj je zdravilo Levetiracetam Actavis Group?
English: How has Levetiracetam Actavis Group been studied?
Slovenian: Kako je bilo zdravilo Levetiracetam Actavis Group raziskano?
English: What is Levetiracetam Actavis Group used for?
Slovenian: Za kaj se zdravilo Levetiracetam Actavis Group uporablja?
English: How is Levetiracetam Actavis Group used?
Slovenian: Kako se zdravilo Levetiracetam Actavis Group uporablja?
English: How does Levetiracetam Actavis Group work?
Slovenian: Kako zdravilo Levetiracetam Actavis Group deluje?
English: The third study involved 59 children aged 2 to 12 years.
Slovenian: Tretja študija je vključevala 59 otrok, starih od 2 do 12 let.
English: Further information on Vihuma can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/Vihuma.
Slovenian: Nadaljnje informacije o zdravilu Vihuma so na voljo na spletni strani agencije:: ema.europa.eu/medicines/human/EPAR/Vihuma.
English: Vihuma received a marketing authorisation valid throughout the EU on 13 February 2017.
Slovenian: Zdravilo Vihuma je pridobilo dovoljenje za promet, veljavno po vsej Evropski uniji, 13. februarja 2017.
English: What measures are being taken to ensure the safe and effective use of Vihuma?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Vihuma?
English: This medicine is the same as Nuwiq, which is already authorised in the EU.
Slovenian: To zdravilo je enako zdravilu Nuwiq, ki je že odobreno v Evropski uniji (EU).
English: Vihuma can be used for short-term or long-term treatment.
Slovenian: Zdravilo Vihuma se lahko uporablja za kratkotrajno ali dolgotrajno zdravljenje.
English: Vihuma (simoctocog alfa)
Slovenian: Vihuma (simoktokog alfa)
English: The European Medicines Agency decided that Vihuma's benefits are greater than its risks and it can be authorised for use in the EU.
Slovenian: Evropska agencija za zdravila je zaključila, da so koristi zdravila Vihuma večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
English: Other information about Vihuma
Slovenian: Druge informacije o zdravilu Vihuma
English: As for all medicines, data on the use of Vihuma are continuously monitored.
Slovenian: Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Vihuma stalno spremljajo.
English: What is Vihuma and what is it used for?
Slovenian: Kaj je zdravilo Vihuma in za kaj se uporablja?
English: What benefits of Vihuma have been shown in studies?
Slovenian: Kakšne koristi je zdravilo Vihuma izkazalo v študijah?
English: Patients or their carers may be able to inject Vihuma themselves at home once they have been trained.
Slovenian: Bolniki ali njihovi negovalci lahko po ustreznem usposabljanju zdravilo Vihuma injicirajo sami doma.
English: What are the risks associated with Vihuma?
Slovenian: Kakšna tveganja so povezana z zdravilom Vihuma?
English: An overview of Vihuma and why it is authorised in the EU
Slovenian: Pregled zdravila Vihuma in zakaj je odobreno v EU
English: Why is Vihuma authorised in the EU?
Slovenian: Zakaj je zdravilo Vihuma odobreno v EU?
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Vihuma have been included in the summary of product characteristics and the package leaflet.
Slovenian: Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Vihuma upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
English: The dose and duration of treatment depend on whether Vihuma is used to treat or prevent bleeding, or during surgery, as well as on the patient's factor VIII levels, the seriousness of the haemophilia, the extent and location of the bleeding and the patient's condition and weight.
Slovenian: Odmerek in trajanje zdravljenja sta odvisna od tega, ali se zdravilo Vihuma uporablja za zdravljenje ali preprečevanje krvavitev ali med kirurškim posegom, ter od ravni faktorja VIII, resnosti hemofilije, obsega in mesta krvavitve ter bolnikovega stanja in telesne mase.
English: The company that makes Nuwiq has agreed that its scientific data can be used for Vihuma (‘informed consent').
Slovenian: Družba, ki proizvaja zdravilo Nuwiq, se strinja, da se lahko znanstveni podatki o tem zdravilu uporabijo tudi za zdravilo Vihuma („uporaba dokumentacije s soglasjem“).
English: Side effects reported with Vihuma are carefully evaluated and any necessary action taken to protect patients.
Slovenian: Neželeni učinki, o katerih so poročali pri zdravilu Vihuma , se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
English: For more information about using Vihuma, see the package leaflet or contact your doctor or pharmacist.
Slovenian: Za več informacij glede uporabe zdravila Vihuma glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
English: It contains the active substance simoctocog alfa (human coagulation factor VIII).
Slovenian: Vsebuje učinkovino simoktokog alfa (humani koagulacijski faktor VIII).
English: A total of 986 bleeding episodes were recorded, most of which resolved with one injection of Vihuma.
Slovenian: Med študijo so zabeležili skupno 986 krvavitev, med katerimi so večino epizod obvladali z eno injekcijo zdravila Vihuma.
English: Vihuma was effective at preventing and treating bleeding episodes in three main studies involving 113 patients with haemophilia A.
Slovenian: Zdravilo Vihuma se je izkazalo za učinkovito pri preprečevanju in zdravljenju krvavitev v treh glavnih študijah, ki so vključevale 113 bolnikov s hemofilijo A.
English: The Agency concluded that Vihuma was effective at treating and preventing bleeding in patients with haemophilia A and it has an acceptable safety profile.
Slovenian: Zaključila je, da se je zdravilo Vihuma izkazalo za učinkovito pri zdravljenju in preprečevanju krvavenja pri bolnikih s hemofilijo A in da ima sprejemljiv varnostni profil.
English: Vihuma is a medicine used for the treatment and prevention of bleeding in patients of all ages with haemophilia A (an inherited bleeding disorder caused by lack of factor VIII).
Slovenian: Vihuma je zdravilo, ki se uporablja za zdravljenje in preprečevanje krvavenja pri bolnikih vseh starosti s hemofilijo A (dedno motnjo strjevanja krvi, ki jo povzroča pomanjkanje faktorja VIII).
English: Some patients treated with factor VIII medicines may develop inhibitors (antibodies) against factor VIII, which may stop the medicine from working and controlling bleeding.
Slovenian: Pri nekaterih bolnikih, zdravljenih z zdravili, ki vsebujejo faktor VIII, se lahko pojavijo zaviralci (protitelesa) faktorja VIII, ki lahko ustavijo delovanje zdravila in nadzor krvavitve.
English: The active substance in Vihuma, simoctocog alfa (human coagulation factor VIII), is a substance that helps the blood to clot.
Slovenian: Učinkovina v zdravilu Vihuma , simoktokog alfa (humani koagulacijski faktor VIII), je snov, ki pripomore k strjevanju krvi.
English: When used to prevent bleeding, an average of 0.19 bleeding episode per month was recorded for each patient.
Slovenian: Kadar so zdravilo uporabljali za preprečevanje krvavitev, so pri vsakem bolniku zabeležili povprečno 0,19 epizode krvavitve na mesec.
English: When used for treating bleeding episodes, Vihuma was mainly rated ‘excellent' or ‘good' at treating major bleeding episodes and most bleeding episodes resolved following one or more injections of Vihuma.
Slovenian: Kadar so zdravilo Vihuma uporabljali za zdravljenje krvavitev, je bilo v glavnem ocenjeno kot „odlično“ ali „dobro“ za zdravljenje večjih krvavitev, večino krvavitev pa so obvladali z eno ali več injekcijami zdravila Vihuma.
English: Patients with haemophilia A lack factor VIII, and this causes blood clotting problems leading to events such as bleeding in the joints, muscles or internal organs.
Slovenian: Bolnikom s hemofilijo A primanjkuje faktorja VIII, kar povzroča motnje strjevanja krvi, kot so krvavenje v sklepe, mišice ali notranje organe.
English: Hypersensitivity (allergic) reactions have been reported with factor VIII medicines and they may be severe in some cases.
Slovenian: Pri uporabi zdravil, ki vsebujejo faktor VIII, so poročali o preobčutljivostnih (alergijskih) reakcijah, ki lahko v nekaterih primerih postanejo hude.
English: For the full list of side effects and restrictions of Vihuma, see the package leaflet.
Slovenian: Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Vihuma glejte navodilo za uporabo.
English: Treatment with Vihuma was rated ‘excellent' or ‘good' for 94% of bleeding episodes.
Slovenian: Zdravljenje z zdravilom Vihuma so pri 94 % krvavitev ocenili kot „odlično“ ali „dobro“.
English: When Vihuma was used for treatment, bleeding episodes resolved in 81% of cases following 1 or 2 injections.
Slovenian: Kadar so ga uporabljali za zdravljenje, so krvavitve v 81 % primerov obvladali z eno ali dvema injekcijama zdravila Vihuma.
English: Vihuma can only be obtained with a prescription, and treatment should be supervised by a doctor experienced in the treatment of haemophilia.
Slovenian: Predpisovanje in izdaja zdravila Vihuma je le na recept, zdravljenje pa mora nadzorovati zdravnik z izkušnjami z zdravljenjem hemofilije.
English: Vihuma corrects the factor VIII deficiency by replacing the missing factor VIII, giving temporary control of the bleeding disorder.
Slovenian: Zdravilo Vihuma se uporablja za uravnavanje pomanjkanja faktorja VIII, in sicer z nadomeščanjem manjkajočega faktorja VIII, kar vzpostavi začasni nadzor nad krvavitvami.
English: When Vihuma was used to prevent bleeding, an average of 0.34 bleeding episode per month was recorded for each child.
Slovenian: Kadar so zdravilo Vihuma uporabljali za preprečevanje krvavitev, so pri vsakem otroku na mesec zabeležili povprečno 0,34 krvavitve.
English: The first study involved 22 patients aged 12 years and above, who were given Vihuma for the treatment of bleeding episodes or to prevent bleeding during surgery.
Slovenian: Prva študija je vključevala 22 bolnikov, starih 12 let in več, ki so prejeli zdravilo Vihuma za zdravljenje krvavitev ali za preprečevanje krvavitve med kirurškim posegom.
English: Vihuma is available as a powder and solvent to mix together to make a solution that is injected into a vein.
Slovenian: Zdravilo Vihuma je na voljo v obliki praška in vehikla, ki se zmešata za pripravo raztopine za injiciranje v veno.
English: How is Vihuma used?
Slovenian: Kako se zdravilo Vihuma uporablja?
English: In the 5 surgeries during the study, Vihuma was rated excellent in preventing bleeding episodes for 4 surgeries and as moderate to prevent bleeding during one surgical intervention.
Slovenian: Pri petih kirurških posegih, ki so jih opravili med študijo, je bilo zdravilo Vihuma pri štirih kirurških posegih ocenjeno kot odlično za preprečevanje krvavitev, pri enem kirurškem posegu pa kot zmerno za preprečevanje krvavitev.
English: How does Vihuma work?
Slovenian: Kako zdravilo Vihuma deluje?
English: The second study involved 32 patients aged 12 years and above who were given Vihuma to prevent and treat bleeding events as well as to prevent bleeding during surgery.
Slovenian: Druga študija je vključevala 32 bolnikov, starih 12 let in več, ki so prejeli zdravilo Vihuma za preprečevanje in zdravljenje krvavitev ter za preprečevanje krvavitve med kirurškim posegom.
English: In the 2 surgeries during the study, Vihuma was rated excellent in preventing bleeding episodes.
Slovenian: Pri dveh kirurških posegih, ki so jih opravili med študijo, je bilo zdravilo Vihuma ocenjeno kot odlično za preprečevanje krvavitev.
English: Onset of immunity: 3 weeks.
Slovenian: Nastop imunosti: 3 tedne.
English: 0.1 mg Colourless suspension.
Slovenian: 0,1 mg Brezbarvna suspenzija
English: When mixed with these Canigen vaccines, the demonstrated safety and efficacy claims for Canigen L4 are no different from those described for Canigen L4 alone.
Slovenian: Kadar se cepivo meša s temi cepivi Canigen, se podatki o varnosti in učinkovitosti za Canigen L4 ne razlikujejo od tistih, ki so opisani za samo cepivo Canigen L4.
English: Basic vaccination: The first vaccination can be administered from 6 to 9(*) weeks of age and the second vaccination from 10 to 13 weeks of age.
Slovenian: Osnovno cepljenje: Prvič lahko cepimo pri starosti od 6 do 9(*) tednov, drugič pa pri starosti od 10 do 13 tednov.
English: 0.1 mg For the full list of excipients, see section 6.1.
Slovenian: Za celoten seznam pomožnih snovi glejte poglavje 6.1.
English: MARKETING AUTHORISATION NUMBER(S) EU/2/15/183/001-003
Slovenian: ŠTEVILKA(E) DOVOLJENJ(A) ZA PROMET EU/2/15/183/001-003
English: Do not use this veterinary medicinal product after the expiry date which is stated on the label.
Slovenian: Tega zdravila za uporabo v veterinarski medicini ne smete uporabljati po datumu izteka roka uporabnosti, navedenega na ovojnini.
English: Franţa,
Slovenian: Francuska,